

Figure 1
 Mean (S.D.) Plasma Dronabinol Concentrations Versus Time
 Linear Scale





Figure 2
Mean Plasma Dronabinol Concentrations Versus Time
Linear Scale



Placebo excluded from figure

Figure 3
Mean Plasma Dronabinol Concentrations Versus Time
Semi-Log Scale





Figure 4


Dose Proportionality Assessment for First Dose Dronabinol, Treatments B, C, D, E, F and G:
C_{max}/Dose Versus Dose (Mean S.D.)



Placebo excluded from figure

Figure 5

Dose Proportionality Assessment for First Dose Dronabinol, Treatments B, C, D, E, F and G:
 $AUC(0-t)/Dose$ Versus Dose (Mean S.D.)



Placebo excluded from figure

Figure 6

Dose Proportionality Assessment for First Dose Dronabinol, Treatments B, C, D, E, F and G:
 $AUC(0-\infty)/Dose$ Versus Dose (Mean S.D.)





Figure 7


Dose Proportionality Assessment for Last Dose Dronabinol, Treatments B, C, D, E, F and G:
C_{max}/Dose Versus Dose (Mean S.D.)



Placebo excluded from figure

Figure 8


Dose Proportionality Assessment for Last Dose Dronabinol, Treatments B, C, D, E, F and G:
AUC(111-135)/Dose Versus Dose (Mean S.D.)



Placebo excluded from figure

Figure 9


Dose Proportionality Assessment for Last Dose Dronabinol, Treatments B, C, D, E, F and G:
C_{min}/Dose Versus Dose (Mean S.D.)



Placebo excluded from figure

Figure 10

Dose Proportionality Assessment for Last Dose Dronabinol, Treatments B, C, D, E, F and G:
Cavg/Dose Versus Dose (Mean S.D.)



Placebo excluded from figure

Figure 11

Mean (S.D.) Plasma 11-OH- Δ^9 -tetrahydrocannabinol Concentrations Versus Time

Linear Scale





Figure 12

Mean Plasma 11-OH- δ -9-tetrahydrocannabinol Concentrations Versus Time


Linear Scale



Placebo excluded from figure

Figure 13


Dose Proportionality Assessment for First Dose 11-OH-delta-9-tetrahydrocannabinol, Treatments B, C, D, E, F and G:
Cmax/Dose Versus Dose (Mean S.D.)



Placebo excluded from figure

Figure 14


Dose Proportionality Assessment for First Dose 11-OH- Δ^9 -tetrahydrocannabinol, Treatments C, D, E, F and G:
AUC(0- ∞)/Dose Versus Dose (Mean S.D.)



Placebo excluded from figure

Figure 15

Dose Proportionality Assessment for First Dose 11-OH- δ^9 -tetrahydrocannabinol, Treatments C, D, E, F and G:
 $AUC(0-\infty)/Dose$ Versus Dose (Mean S.D.)



Placebo excluded from figure

Figure 16

Dose Proportionality Assessment for Last Dose 11-OH- δ 9-tetrahydrocannabinol, Treatments C, D, E, F and G:
Cmax/Dose Versus Dose (Mean S.D.)





Figure 17


Dose Proportionality Assessment for Last Dose 11-OH-delta-9-tetrahydrocannabinol, Treatments C, D, E, F and G:
AUC(111-135)/Dose Versus Dose (Mean S.D.)



Placebo excluded from figure

Figure 18


Dose Proportionality Assessment for Last Dose 11-OH- δ^9 -tetrahydrocannabinol, Treatments C, D, E, F and G:
Cmin/Dose Versus Dose (Mean S.D.)



Placebo excluded from figure

Figure 19

Dose Proportionality Assessment for Last Dose 11-OH- Δ^9 -tetrahydrocannabinol, Treatments C, D, E, F and G:
Cavg/Dose Versus Dose (Mean S.D.)



Placebo excluded from figure

Figure 20

Mean (S.D.) Pulse Rate Versus Time

Linear Scale





Figure 21

Mean Pulse Rate Versus Time
Linear Scale



Placebo excluded from figure

Figure 22

Mean Pulse Rate Versus Time
Semi-Log Scale




Figure 23

Mean (S.D.) Conjunctiva Congestion Versus Time
Linear Scale




Figure 24

Mean Conjunctiva Congestion Versus Time

Linear Scale





Figure 25

Mean Conjunctiva Congestion Versus Time

Semi-Log Scale






Figure 26. Plasma concentration-time profile of dronabinol after single dose administration of dronabinol via oral and pulmonary delivery routes.




Figure 27. Plasma concentration-time profile of the 11-OH metabolite after single dose administration of dronabinol via oral and pulmonary delivery routes.




Figure 28. Plasma concentration-time profile of dronabinol after multiple dose administration of dronabinol via pulmonary delivery.




Figure 29. Plasma concentration-time profile of the 11-OH metabolite after multiple dose administration of dronabinol via pulmonary delivery.